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Risk Factors for In-hospital Nonhemorrhagic Stroke in
Patients With Acute Myocardial Infarction
Treated With Thrombolysis
Results From GUSTO-I
Kenneth W. Mahaffey, MD; Christopher B. Granger, MD; Michael A. Sloan, MD;
Trevor D. Thompson, BS; Joel M. Gore, MD; W. Douglas Weaver, MD; Harvey D. White, MB, DSc;
Maarten L. Simoons, MD; Gabriel I. Barbash, MD, MPH; Eric J. Topol, MD;
Robert M. Califf, MD; for the GUSTO-I Investigators
Background—Nonhemorrhagic stroke occurs in 0.1% to 1.3% of patients with acute myocardial infarction who are treated with
thrombolysis, with substantial associated mortality and morbidity. Little is known about the risk factors for its occurrence.
Methods and Results—We studied the 247 patients with nonhemorrhagic stroke who were randomly assigned to one of four
thrombolytic regimens within 6 hours of symptom onset in the GUSTO-I trial. We assessed the univariable and multivariable
baseline risk factors for nonhemorrhagic stroke and created a scoring nomogram from the baseline multivariable modeling. We
used time-dependent Cox modeling to determine multivariable in-hospital predictors of nonhemorrhagic stroke. Baseline and
in-hospital predictors were then combined to determine the overall predictors of nonhemorrhagic stroke. Of the 247 patients,
42 (17%) died and another 98 (40%) were disabled by 30-day follow-up. Older age was the most important baseline clinical
predictor of nonhemorrhagic stroke, followed by higher heart rate, history of stroke or transient ischemic attack, diabetes,
previous angina, and history of hypertension. These factors remained statistically significant predictors in the combined model,
along with worse Killip class, coronary angiography, bypass surgery, and atrial fibrillation/flutter.
Conclusions—Nonhemorrhagic stroke is a serious event in patients with acute myocardial infarction who are treated with
thrombolytic, antithrombin, and antiplatelet therapy. We developed a simple nomogram that can predict the risk of
nonhemorrhagic stroke on the basis of baseline clinical characteristics. Prophylactic anticoagulation may be an important
treatment strategy for patients with high probability for nonhemorrhagic stroke, but further study is needed. (Circulation.
1998;97:757-764.)
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S troke is one of the most feared complications in patientswith acute myocardial infarction. In the era before the
routine use of thrombolytic therapy and anticoagulation,
stroke was observed in 1.7% to 3.2% of patients.1–5 Intracranial
hemorrhage was exceedingly rare. In the thrombolytic era, the
overall incidence of stroke in large clinical trials is lower, but
the types of strokes have changed. Nonhemorrhagic stroke
now occurs in 0.1% to 1.3% of patients, and intracranial
hemorrhage occurs in 0.07% to 1.5% of patients.6–12
Recently, multivariable regression models have been devel-
oped to help identify patients at increased risk for intracranial
hemorrhage after thrombolysis, including a model based on the
GUSTO-I trial experience.7–9,13–16 Less is known about the risk
factors for nonhemorrhagic stroke in patients with acute
myocardial infarction treated with thrombolytic therapy, al-
though several investigators have reported clinical and echo-
cardiographic factors associated with an increased risk for
nonhemorrhagic stroke.7,8,10–12,17–25
We used prospectively collected information from the
GUSTO-I trial for patients with and without nonhemorrhagic
stroke to determine independent risk factors associated with
in-hospital nonhemorrhagic stroke in patients with acute
myocardial infarction treated with thrombolytic therapy.
Methods
Study Population
The study population was the 41 021 patients enrolled in the
GUSTO-I trial.26 In brief, patients presenting with acute myocardial
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infarction within 6 hours of symptom onset were randomly assigned to
one of four thrombolytic strategies: (1) 1.5 million U streptokinase IV
over 1 hour and 12 500 heparin U SC BID; (2) 1.5 million U
streptokinase IV over 1 hour and 5000 U heparin IV bolus followed
by 1000 U/h; (3) alteplase in an accelerated regimen (15-mg IV bolus
followed by 0.75 mg/kg over 30 minutes and then 0.5 mg/kg over the
next hour) and 5000 U heparin IV bolus followed by 1000 U/h; or (4)
both 1 million U streptokinase and 1.0 mg/kg alteplase IV over 1 hour
and 5000 U heparin IV bolus followed by 1000 U/h. All patients
received aspirin (160 to 325 mg) daily. The overall experience with
stroke in the GUSTO-I has been previously reported.9
Definitions
Nonhemorrhagic Stroke
Nonhemorrhagic stroke was defined as an acute new neurological
deficit resulting in death or lasting for .24 hours without hemorrhage
on computed tomography or magnetic resonance imaging, as classified
by a physician with supporting documentation from discharge sum-
maries, progress notes, brain images, neurological/neurosurgical eval-
uation, or autopsy reports.
Sustained Hypotension
Sustained hypotension was defined as systolic blood pressure of
,90 mm Hg for .1 hour despite fluid replacement.
Cardiogenic Shock
Cardiogenic shock was defined as systolic blood pressure of
,90 mm Hg for $1 hour, not responsive to fluid replacement alone,
thought to be secondary to cardiac dysfunction, and associated with
signs of hypoperfusion (cool, clammy skin, oliguria, or altered
sensorium or cardiac index of #2.2 L z min21 z /m22). If the systolic
blood pressure increased to .90 mm Hg as a result of positive
inotropic agents alone within 1 hour, this was still classified as
cardiogenic shock.
Congestive Heart Failure
Congestive heart failure was considered to be signs or symptoms of
congestion (rales above the lung base, dyspnea, pulmonary edema on
chest radiograph, or peripheral edema) or low cardiac output (weak-
ness, fatigue) thought to be secondary to cardiac dysfunction.
Killip Class
Killip class I was defined as the absence of rales over the lung fields and
the absence of S3 gallop. Class II included patients who had rales across
#50% of the lung fields or the presence of an S3 gallop. Class III was
defined as rales across .50% of the lung fields, and class IV was defined
as pulmonary edema with hypoperfusion (cardiogenic shock).
Ejection Fraction
Ejection fraction was determined by the site investigator at the time of
cardiac catheterization and, therefore, is available only for patients
undergoing angiography.
Data Collection
The evaluation of patients with stroke and the collection of specific
data about stroke treatment and clinical outcomes in the trial were
prospectively planned. The protocol specified that all patients with a
new focal neurological deficit undergo a complete evaluation includ-
ing brain imaging. Patients with nonhemorrhagic stroke were identi-
fied from the responses to specific questions on the Case Report Form
or from a two-page supplemental Stroke Details Form, which was
completed for each patient with a suspected stroke. In addition, the
study collected available supporting documents, such as physicians’
notes, operative reports, discharge summaries, autopsy reports, and
results of computed tomographic and magnetic resonance imaging
studies.
Nonhemorrhagic Stroke Adjudication
A Stroke Review Committee (see “Appendix”) was established to
adjudicate and categorize all suspected strokes. For each suspected
nonhemorrhagic stroke, the medical records and brain imaging studies
were independently reviewed by two teams, each consisting of a
cardiologist and neurologist. Each team was responsible for determin-
ing whether a nonhemorrhagic stroke had occurred. Disagreements
were resolved by a third team.
Patient Functional Assessment
Functional status was determined for all patients with nonhemorrhagic
stroke at hospital discharge or 30 days, whichever came first. Patients
were classified as not disabled if they had no deficit (no sequelae) or
minor deficits (functional status unchanged) and as disabled if they had
moderate deficits (significant limitations of activity) or severe deficits
(unable to live independently or work).9
Statistical Analysis
Continuous variables are shown as medians with 25th, and 75th
percentiles; discrete variables are shown as frequencies and percent-
ages. Cox proportional hazards modeling was used to determine the
univariable predictors of nonhemorrhagic stroke and determine the
multivariable baseline risk factors for nonhemorrhagic stroke. When
examining the effect of interventions on nonhemorrhagic stroke, we
considered that some patients may have had a nonhemorrhagic stroke
before they could receive an intervention or may have had a planned
intervention canceled. Crediting the nonintervention group with all
of these early events would unfairly inflate the lack of association of
the stroke and the intervention. As a result, we used time-dependent
Cox modeling to determine multivariable in-hospital predictors of
nonhemorrhagic stroke. The interventions included as time-depen-
dent covariates were cardiac catheterization, percutaneous translumi-
nal coronary angioplasty, coronary artery bypass graft surgery, and
intra-aortic balloon counterpulsation. In-hospital congestive heart
failure and cardiogenic shock were similarly treated as time-dependent
covariates. A backward-elimination method was used to determine
the significant predictors from the baseline and in-hospital analyses
(elimination criterion, P,.05). Baseline and in-hospital predictors
were then combined to determine the overall predictors of nonhem-
orrhagic stroke. Predictors in each analysis were tested using the
likelihood ratio x2 test. Results are also presented as hazard ratios and
95% confidence intervals.
We created a scoring nomogram on the basis of coefficients from
the baseline multivariable regression modeling. Each independent
predictor was assigned a particular score according to its predictive
value. The sum of the scores indicates the probability of a nonhem-
orrhagic stroke based on baseline predictors for individual patients
(F. E. Harrell: Design S plus functions for biostatistical/epidemiolog-
ical modeling, testing, estimation, validation, graphics, prediction, and
typesetting by storing enhanced model design attributes in the fit.
UNIX version available from statlib@lib.stat.cmu.edu; 1996).
Results
There were 247 patients with nonhemorrhagic stroke in the
GUSTO-I population (0.6%), of whom 42 (17%) died. In all,
56.7% of patients with nonhemorrhagic stroke died or were
disabled at the time of hospital discharge (Table 1).
The baseline clinical characteristics for the 246 patients with
in-hospital nonhemorrhagic stroke (1 patient had a nonhem-
orrhagic stroke after hospital discharge and 30-day follow-up
and is not included in the analyses) and the 40 688 patients
without nonhemorrhagic stroke are shown in Table 2. Patients
with nonhemorrhagic stroke were older and more often female
and had a higher incidence of previous coronary disease,
hypertension, and diabetes. They also tended to have a worse
baseline Killip class and more often had atrial fibrillation/flutter
and anterior infarcts at enrollment.
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Patients with nonhemorrhagic stroke were more likely to
have adverse in-hospital events and bypass surgery (Table 3).
The univariable x2 values and hazard ratios for the baseline and
in-hospital factors associated with in-hospital nonhemorrhagic
stroke are shown in Tables 4 and 5.
Baseline Multivariable Predictors
Six baseline clinical and historical characteristics were signifi-
cant independent predictors of in-hospital nonhemorrhagic
stroke (Table 6). Age was the most important baseline clinical
predictor. Higher heart rate, history of stroke or transient
ischemic attack, diabetes, previous angina, and history of
hypertension were the other statistically significant baseline
predictors. Atrial fibrillation/flutter on the baseline ECG and
Killip class at the time of enrollment were not statistically
significant independent predictors of nonhemorrhagic stroke
(x253.13, P5.08; and x255.23, P5.16, respectively). The
predicted probability of nonhemorrhagic stroke based on
baseline clinical and historical data can be calculated for
individual patients with the nomogram shown in Fig. 1.
In-hospital Multivariable Predictors
Worse Killip class was the most potent predictor for nonhem-
orrhagic stroke, followed by atrial fibrillation/flutter and per-
formance of coronary artery bypass surgery and cardiac cath-
eterization (Table 7). In the analysis of in-hospital factors,
patients with atrial fibrillation/flutter at baseline were com-
pared with those who did not have atrial fibrillation/flutter at
baseline and did not develop the arrhythmia during the
hospital stay. In addition, patients who develop atrial fibrilla-
tion/flutter during hospitalization were compared with pa-
tients without atrial fibrillation at baseline or in-hospital.
Patients developing atrial fibrillation/flutter after enrollment
had a greater than twofold higher incidence of nonhemor-
rhagic stroke than patients who did not have atrial fibrillation/
flutter at baseline or during hospitalization (hazard ratio, 2.08;
95% confidence interval, 1.52 to 2.86). Patients with atrial
fibrillation/flutter at baseline also had a higher likelihood of
nonhemorrhagic stroke than patients who never had atrial
fibrillation/flutter during the hospital stay (hazard ratio, 2.44;
95% confidence interval, 1.43 to 4.16).
TABLE 1. Clinical Outcomes
Outcome
No. of Patients (%)
(N5247)
Death 42 (17.0)
Severe deficit 39 (15.8)
Moderate deficit 59 (23.9)
Mild deficit 70 (28.3)
No deficit 23 (9.3)
Unknown 14 (5.7)





Median age, y 69 (62, 75) 61 (52, 70)
Female, n (%) 77 (31.3) 10 227 (25.1)
Systolic blood pressure, mm Hg 130 (115, 148) 130 (112, 144)
Diastolic blood pressure, mm Hg 80 (69, 90) 80 (70, 90)
Killip class
I 188 (76.4) 34 585 (85.4)
II 43 (17.5) 5073 (12.5)
III 10 (4.1) 537 (1.3)
IV 5 (2.0) 309 (0.8)
Heart rate, bpm 77 (64, 93) 74 (62, 86)
Anterior infarction, n (%) 109 (44.5) 15 825 (39.0)
Previous infarction, n (%) 67 (27.5) 6627 (16.3)
Height, cm 171 (165, 177) 172 (165, 178)
Time to treatment, h 3 (2, 4) 3 (2, 4)
History of smoking, n (%) 162 (66.9) 28 023 (69.5)
Current smoking, n (%) 76 (30.9) 17 416 (43.0)
Diabetes mellitus, n (%) 66 (26.9) 5935 (14.6)
Median weight, kg 76 (68, 85) 78 (70, 88)
Previous bypass surgery, n (%) 22 (8.9) 1757 (4.3)
Previous angioplasty, n (%) 11 (4.5) 1629 (4.0)
Previous angina, n (%) 128 (52.5) 14 903 (36.8)
History of hypertension, n (%) 131 (53.3) 15 398 (38.0)
Hyperlipidemia, n (%) 78 (32.4) 13 497 (34.3)
Atrial fibrillation/flutter, n (%) 15 (6.3) 967 (2.5)
Values are given as median (25th and 75th percentiles) or frequency (percentages).
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Combined Multivariable Predictors
All 10 independent predictors from the baseline and in-hospital
multivariable analyses except history of hypertension remained
statistically significant, independent predictors of nonhemor-
rhagic stroke in the combined analysis (Table 8). Worse Killip
class and older age were the two most important predictors,
followed by performance of cardiac catheterization and bypass
surgery. A second combined analysis included only the 15 220
(37.1%) patients undergoing angiography who had a docu-
mented ejection fraction (Table 9). Age, performance of
cardiac catheterization, and bypass surgery were significant and
potent independent predictors of nonhemorrhagic stroke.
Lower ejection fraction, higher heart rate, diabetes, and worse
Killip class had borderline statistical significance as predictors of
nonhemorrhagic stroke in the combined model of patients
with known ejection fraction. Atrial fibrillation/flutter, previ-
ous angina, previous hypertension, and stroke or transient
ischemic attack were no longer statistically significant indepen-
dent predictors.
Discussion
Stroke is a well-documented event in patients with acute
myocardial infarction. The routine use of anticoagulant and
thrombolytic therapies has reduced the occurrence of non-
hemorrhagic stroke but increased the risk of intracranial
hemorrhage. Nonhemorrhagic stroke, however, is associ-
ated with significant morbidity and mortality.9 We identi-
fied six easily determined baseline patient clinical and
historical factors (older age, higher heart rate, history of
stroke or transient ischemic attack, diabetes, previous an-
gina, and history of hypertension) that independently pre-
dict nonhemorrhagic stroke in patients with acute myocar-
dial infarction treated with thrombolysis, heparin, and
aspirin. In addition, four common in-hospital characteristics
(worse Killip class, atrial fibrillation/flutter, bypass surgery,
and cardiac catheterization) are independently associated
with nonhemorrhagic stroke.
Several investigators have reported that patients with in-
creased age,7,8,10 anterior myocardial infarction,8,10,11 and worse
Killip class7,10 are at increased risk for nonhemorrhagic stroke.
In our analysis, anterior infarct was not a univariable predictor
of nonhemorrhagic stroke, although there was a trend toward
a higher incidence of anterior infarction in patients with
nonhemorrhagic stroke than in those without stroke (44.5%
versus 39.0%; P5.13). In addition, isolated apical infarct and
combined anteroapical infarct also were not statistically signif-
icant univariable predictors of nonhemorrhagic stroke
(x250.75, P5.39; and x253.23, P5.072, respectively).





Ejection fraction, % 45 (35, 53)* 51 (43, 60)†
Sustained hypotension, n (%) 52 (21.2) 4824 (11.9)
Worse Killip class, n (%)
I 75 (30.7) 26 618 (65.9)
II 104 (42.6) 10 177 (25.2)
III 35 (14.3) 1774 (4.4)
IV 30 (12.3) 1854 (4.6)
Atrial fibrillation/flutter, n (%)‡ 59 (24.0) 3214 (7.9)
Cardiac catheterization, n (%)
Total 136 (55.5) 22 169 (54.6)
Before stroke onset§ 109 (44.7)
Angioplasty, n (%)
Total 38 (15.6) 8701 (21.5)
Before stroke onset§ 27 (11.1)
Bypass surgery, n (%)
Total 48 (19.5) 3433 (8.5)
Before stroke onset§ 40 (16.3)
Intra-aortic balloon counterpulsation, n (%)
Total 21 (8.6) 1458 (3.6)
Before stroke onset§ 20 (8.2)
Congestive heart failure, n (%)
Total 95 (38.6) 6535 (16.1)
Before stroke onset§ 71 (29.7)
Cardiogenic shock, n (%)
Total 29 (11.8) 2412 (5.9)
Before stroke onset§ 25 (10.2)
*n594, †n515 956, ‡after enrollment, §occurring on same day as or before stroke onset.
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From 28% to 40% of patients with anterior infarction and
0% to 1.5% of patients with inferior infarction have a left
ventricular thrombus, according to small echocardiographic
studies performed primarily in the era before the routine use of
thrombolysis and aggressive anticoagulation.17–20,23–25 The inci-
dence of systemic embolization was 0% to 33% in patients with
documented thrombus, lower in patients receiving anticoagu-
lation, and exceedingly rare in patients with no observed
thrombus.17–25 Echocardiographic features associated with an
increased risk of embolization include older age,19 larger
thrombus size,19 thrombus mobility,20–23 and pendulousness of
the clot.19–23 Because echocardiography was not mandated by
the GUSTO-I protocol, the incidence of left ventricular
thrombus in the GUSTO-I population is unknown. In addi-
tion, data were not collected on warfarin therapy, which may
have influenced these findings. Further study is required to
clarify the relationship among location of infarction, incidence
of thrombus, impact of anticoagulation, and risk of nonhem-
orrhagic stroke.
The incidence of stroke associated with the procedures and
events that this study found to correlate with increased risk of
nonhemorrhagic stroke—specifically, atrial fibrillation/flutter,
cardiac catheterization, and coronary artery bypass surgery—
has been well established by previous investigators. The risk of
stroke in patients with nonvalvular atrial fibrillation is '5% per
year, or a fivefold to sevenfold higher incidence compared
with patients without the arrhythmia.27,28 Several large regis-
tries have reported that stroke occurs in ,0.01% of patients
undergoing cardiac catheterization.29,30 The incidence of stroke
in patients undergoing coronary artery bypass surgery has been
reported to occur in 0.4% to 5.4% of patients.31–33 One of the
largest most comprehensive multicenter series reported nonfa-
tal stroke in 2.6% of patients after coronary artery bypass
surgery.34
A unique aspect of this study was the incorporation of
in-hospital events in the analysis, to examine not only baseline
clinical characteristics but also in-hospital factors common in
patients after acute myocardial infarction—such as atrial ar-
rhythmias, coronary interventions, and bypass surgery—that
may predict nonhemorrhagic stroke. The finding of the
Fibrinolytic Therapy Trialists’ Cooperative Group that 62% of
the nonhemorrhagic strokes in patients treated with
thrombolysis occurred .24 hours after enrollment emphasizes
the importance of this analysis.6 In addition, 60% of nonhem-
orrhagic strokes in the GUSTO-I trial occurred .48 hours
after randomization (Fig. 2).9
Study Limitations
Our study has several limitations. An important aspect of the
study was the time-dependent analysis of clinical events and
procedures in relation to the onset of stroke symptoms. The
time of onset for atrial fibrillation or worse Killip class was not
known, so only the day of occurrence was used in the
time-dependent analysis and compared with the day of stroke
TABLE 4. Univariable Baseline Predictors of
Nonhemorrhagic Stroke
Patient Characteristic x2 P Hazard Ratio
Older age (per 10 y) 81.6 ,.001 1.7
History of stroke or transient ischemic attack 26.6 ,.001 4.3
Diabetes 25.1 ,.001 2.2
History of hypertension 21.8 ,.001 1.8
Previous angina 20.3 ,.001 1.8
Previous infarction 19.6 ,.001 2.0
Higher heart rate (per 10 bpm) 19.1 ,.001 1.2
Killip class 19.1 ,.001
II vs I 1.5
III vs I 3.4
IV vs I 3.7
Current smoker 13.6 ,.001 0.6
Atrial fibrillation/flutter (at enrollment) 9.7 .002 2.6
Previous bypass surgery 8.8 .003 2.1
Higher weight (per 10 kg) 6.1 .01 0.9
Female gender 4.0 .04 1.3
Infarct location (anterior vs other) 2.3 .13 1.2
Systolic blood pressure (per 10 mm Hg) 0.8 .36 1.0
Diastolic blood pressure (per 10 mm Hg) 0.3 .58 1.0
Time to treatment (per 10 minutes) 0.02 .88 0.9
TABLE 5. Univariable In-hospital Predictors of
Nonhemorrhagic Stroke
Patient Characteristic x2 P Hazard Ratio
Killip class 122.3 ,.001
II vs I 3.3
III vs I 5.8
IV vs I 6.5
Atrial fibrillation/flutter 59.4 ,.001
At baseline vs none 3.2
Developed in-hospital vs none 3.4
Congestive heart failure 44.4 ,.001 2.8
Bypass surgery 42.2 ,.001 4.2
Cardiac catheterization 22.7 ,.001 2.0
Sustained hypotension 18.3 ,.001 2.1
Lower ejection fraction (per 10%) 17.7 ,.001 1.4
Cardiogenic shock 16.3 ,.001 2.6
Intra-aortic balloon pump
counterpulsation 15.1 ,.001 2.9
Angioplasty 0.02 .88 1.0
TABLE 6. Multivariable Baseline Predictors of
Nonhemorrhagic Stroke
x2* P Hazard Ratio (95% CI)
Older age (per 10 y) 60.9 ,.001 1.60 (1.41-1.80)
Increased heart rate (per 10 bpm) 15.1 ,.001 1.13 (1.07-1.21)
History of stroke or TIA 11.6 .001 2.55 (1.58-4.10)
Diabetes 10.9 .001 1.66 (1.24-2.21)
Previous angina 10.6 .001 1.53 (1.18-1.97)
History of hypertension 6.2 .013 1.39 (1.07-1.80)
TIA indicates transient ischemic attack.
*Model x25147.8; 39 942 patients with 242 events included in modeling.
Mahaffey et al 761
symptom onset. Dates and times for cardiac interventions and
other in-hospital events were available.
Because information was not collected about the use of
warfarin therapy, the impact of anticoagulation in this patient
population cannot be assessed. In addition, information was
not collected about postdischarge events (other than mortality
and procedures that may be associated with nonhemorrhagic
stroke). However, only one nonhemorrhagic stroke occurred
after hospital discharge and before 30-day follow-up. A pro-
portion of the GUSTO-I population may have had a cerebro-
vascular event that was pathophysiologically related to the
index myocardial infarction .30 days after enrollment.
In the in-hospital model, patients who presented with or
developed atrial fibrillation/flutter (compared with those with-
out the arrhythmia) were at higher risk for nonhemorrhagic
stroke. However, in the baseline multivariable model, atrial
fibrillation/flutter at enrollment did not independently predict
nonhemorrhagic stroke. Duration of atrial fibrillation/flutter
before enrollment, which we were unable to assess, may have
been a contributing factor.
The GUSTO-I stroke dataset, which included 247 non-
hemorrhagic stroke patients, is the largest single-trial experi-
ence to date. The systematic review of all suspected strokes by
the Stroke Review Committee and the availability of com-
puted axial tomographic, magnetic resonance imaging, or
autopsy data for 93% of stroke patients resulted in definitive
classification of stroke subtypes; thus, the number of “un-
knowns” was small. The mechanism of nonhemorrhagic stroke
was not determined, and some strokes may not have been
related to cardiac events or procedures. Despite the relatively
large numbers, the sample size still limited the ability to
perform more extensive multivariable regression modeling.
Figure 1. Nomogram for the prediction of
nonhemorrhagic stroke after thrombolysis for
acute myocardial infarction. CVD indicates
cerebrovascular disease. In 1, find the value
most closely matching the patient’s risk fac-
tors and circle the corresponding point
assignment. In 2, sum the points for all pre-
dictive factors. In 3, determine the probability
of in-hospital nonhemorrhagic stroke. For
example, a 71-year-old nondiabetic patient
with previous CVD, a history of hypertension,
and previous angina who presents with a
heart rate of 121 bpm would have a total
score of 601321012017195128. This score
corresponds to a predicted probability of in-
hospital nonhemorrhagic stroke of 10%.
TABLE 7. Multivariable In-hospital Predictors of
Nonhemorrhagic Stroke
x2* P Hazard Ratio (95% CI)
Killip class 84.1 ,.001
II vs I 2.95 (2.17-4.01)
III vs I 4.50 (2.94-6.89)
IV vs I 5.01 (3.20-7.84)
Atrial fibrillation/flutter 24.4 ,.001
At baseline vs none 2.44 (1.43-4.16)
Developed in-hospital vs none 2.08 (1.52-2.86)
Bypass surgery 13.0 ,.001 2.25 (1.47-3.42)
Cardiac catheterization 8.4 .004 1.60 (1.17-2.19)
*Model x25180.6; 38 417 patients with 235 events.
TABLE 8. Combined (Baseline and In-hospital) Multivariable
Predictors of Nonhemorrhagic Stroke
x2* P Hazard Ratio (95% CI)
Killip class 46.8 ,.001
II vs I 2.34 (1.71-3.19)
III vs I 3.01 (1.94-4.66)
IV vs I 3.51 (2.22-5.53)
Older age (per 10 y) 35.1 ,.001 1.47 (1.29-1.68)
Cardiac catheterization 14.5 ,.001 1.87 (1.37-2.57)
Bypass surgery 13.4 ,.001 2.28 (1.50-3.48)
Atrial fibrillation/flutter 11.8 .003
At baseline vs none 1.81 (1.05-3.11)
Developed in-hospital vs none 1.68 (1.22-2.32)
Previous angina 10.0 .002 1.52 (1.17-1.97)
History of stroke or TIA 9.3 .002 2.28 (1.42-3.68)
Diabetes 7.9 .005 1.55 (1.15-2.08)
Higher heart rate (per 10 bpm) 6.1 .014 1.09 (1.02-1.16)
History of hypertension 3.8 .0503 1.30 (1.00-1.69)
TIA indicates transient ischemic attack.
*Model x25267.7; 38 256 patients with 233 events included in modeling.
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Finally, these results are only applicable to the patients with
acute myocardial infarction treated with thrombolytic therapy
and should not be generalized to all patients with acute
myocardial infarction.
Conclusions
Nonhemorrhagic stroke remains a serious event in patients
with acute myocardial infarction treated with thrombolytic,
antithrombin, and antiplatelet therapy and is associated with
significant morbidity and mortality. Older age, higher heart
rate, history of stroke or transient ischemic attack, diabetes,
previous angina, and history of hypertension are independent
clinical and historical predictors of nonhemorrhagic stroke;
physicians can use these factors to determine the baseline
probability of nonhemorrhagic stroke with a simple scoring
nomogram (Fig 1). This information may enhance awareness
of the potential for nonhemorrhagic stroke early after myocar-
dial infarction. Beyond the baseline characteristics, adverse
in-hospital cardiac events, such as worsening Killip class, atrial
fibrillation/flutter, and performance of cardiac catheterization
or bypass surgery also are potent, independent predictors of
nonhemorrhagic stroke.
Patients with several risk factors or a high probability for
nonhemorrhagic stroke may benefit from prophylactic antico-
agulation, but further study is needed.
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